Passive antibody therapy in emerging infectious diseases.
10.1007/s11684-023-1021-y
- Author:
Xiaoming YANG
1
Author Information
1. National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China. yangxiaoming@sinopharm.com.
- Publication Type:Review
- Keywords:
COVID-19;
SARS-CoV-2;
convalescent plasma;
hyperimmunoglobulin;
neutralizing monoclonal antibodies
- MeSH:
Humans;
Antibodies, Viral/therapeutic use*;
Communicable Diseases, Emerging/drug therapy*;
COVID-19 Drug Treatment;
COVID-19/therapy*;
SARS-CoV-2;
Antibodies, Neutralizing
- From:
Frontiers of Medicine
2023;17(6):1117-1134
- CountryChina
- Language:English
-
Abstract:
The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 years. Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonal antibodies (mAbs) applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment. In this review, the development path, action mechanism, clinical research results, challenges, and safety profile associated with the use of COVID-19 convalescent plasma, hyperimmunoglobulin, and mAbs were summarized. In addition, the prospects of applying antibody therapy against VOCs was assessed, offering insights into the coping strategies for facing new infectious disease outbreaks.
